



All.Can at six years: annual report 2022

All.Can International is a not-for-profit organisation (ASBL) registered in Belgium.

Its work is made possible with financial support from Bristol Myers Squibb, Roche, MSD, Johnson & Johnson and Illumina. Additional financial support for projects has been provided by Amgen.



Mission

All.Can is the global multi-stakeholder platform for cancer care efficiency, aiming to improve health outcomes for cancer patients around the world.

We collaborate to advance efficiency in cancer care for the benefit of patients and society.

We do so by generating, promoting and advocating for evidence-based and measurable improvements in cancer care research, policy and practice.

Vision

We imagine a world in which patients are always at the heart of cancer care.

We work together for efficient, equitable and sustainable cancer care that focuses on what matters to patients and society.

All.Can's work is guided by three Key Principles:



Put patients first - Define and deliver cancer care efficiency according to what matters most to patients and society.



Adopt a whole-system perspective - Eliminate inefficiencies across the entire cancer care pathway and spectrum.



Promote multi-stakeholder collaboration - Harness the strengths of all cancer care stakeholders.





Contents

All.Can's Key Achievements in 2022.....	5
---	---

Foreword.....	6
---------------	---

Advancing Thought Leadership

Efficiency in Cancer Care Blueprint.....	6
--	---

Cancer Efficiency Metrics study.....	8
--------------------------------------	---

“How to improve efficiency in cancer care: Dimensions, methods, and areas of evaluation” in Journal of Cancer Policy.....	9
---	---

Driving Policies and Dialogue

All.Can Global Summit 2022.....	10
---------------------------------	----

All.Can's feedback on EU Cancer screening recommendation update.....	12
--	----

Efficiency in Cancer Care Blueprint launch event.....	13
---	----

Improving Systems and Pathways Globally and Locally

Collaborations & Partnerships.....	14 and 15
------------------------------------	-----------

External Engagements.....	16
---------------------------	----

All.Can at Events.....	17
------------------------	----

All.Can in the Media.....	18
---------------------------	----

Efficiency Hub – Lessons Learnt.....	19
--------------------------------------	----

Members.....	20
--------------	----

National Initiatives.....	21 to 44
---------------------------	----------

All.Can's Key Achievements in 2022

Advancing thought leadership



- Blueprint on Efficiency in Cancer Care
- Efficiency Metrics in Cancer Care study
- 44 case studies on the Efficiency Hub & quoted by EU Commission Cancer Mission Board report
- 5 Articles published

Driving policies and dialogue



- Policy submission on EU cancer screening guidelines
- Submitted 3 EU-funded projects (2 granted)
- All.Can Global Summit
 - 260 participants from 40 countries, 26 panelists
- All.Can Speakers/Representation at 13 international events
- All.Can Social Media Followers
 - 1352 Twitter 1036 LinkedIn (+50% year-on-year)

Global Collaboration



- 19 All.Can National Initiatives
- 30 Organisations and 9 Individual Members
- Joined global ATOM Coalition, continued collaboration with European Alliance on Value in Health on VBHC; EU Health Coalition on Innovation and Health Systems

Foreword

With 2022 marking the sixth year of All.Can's existence and its third since gaining official recognition as a not-for-profit association, our Mission to improve health outcomes for people affected by cancer around the world has been advanced through policy research and advocacy actions. These have been aimed at promoting accessible, patient-centric, evidence-based and high-quality care to achieve the best possible outcomes and experience for all people affected by cancer.

We aspire to continue driving progress towards adaptive and learning healthcare systems, that allow for better and more equitable use of resources today and in the future.

Building on these principles, the All.Can Board of Directors has provided enthusiastic guidance towards implementing significant projects guided by our strategic goals. These range from advancing thought leadership, to driving dialogue and policies, to improving systems and pathways globally and locally.

- In 2022, All.Can published several opinion-leading publications of which we are very proud, starting with the "Blueprint on Efficiency in Cancer Care", launched in February, during a virtual session hosted by Tomislav Sokol, Member of the European Parliament, followed by the "Efficiency Metrics in Cancer Care" study, carried out by the University of Southampton, UK and The Health Value Alliance. "Achieving Efficiency in Practice – lessons learnt from the All.Can Efficiency Hub", an analysis conducted by The Health Policy Partnership, was released in August. Finally, a peer-reviewed article on cancer care efficiency co-authored by several All.Can members and driven by Bocconi University, Italy was published in the Journal of Cancer Policy.
- The All.Can Global Summit, held in June, welcomed 26 panellists and over 260 participants from 40 countries, bringing together policymakers, healthcare professionals, and civil society.
- Diverse and innovative projects have been launched by All.Can National Initiatives global network, ranging from cancer care navigation in Australia, cancer patient surveys in Argentina and Colombia, survivorship and early diagnosis in Belgium, to optimising cancer diagnosis in Canada. These initiatives highlight the vibrant and meaningful impact of the All.Can global community.
- Our partnerships and collaborations with other organisations have also been instrumental in integrating All.Can's definition of cancer care efficiency and evidence-based recommendations into significant projects and activities. These include the launch of the ATOM Coalition (Access to Oncology Medicines) led by the UICC and the launch of policy recommendations by the EU Health Coalition. For the first time, in a significant development for the organisation, All.Can joined in consortia with other key stakeholders to participate in EU-funded projects. Two of those proposals were successfully granted and will commence in 2023.
- Our communications activities have served to enhance the visibility of our work throughout the year, with an expanded social media presence, articles published in various news outlets, and participation in numerous conferences and workshops.

With 2023 set to be another momentous year for cancer policy globally, with gratitude for the commitment of the Board members and our dynamic Working Groups, we look forward to continuing working with all the members and colleagues in the global All.Can community to capitalise on current opportunities and create further possibilities to fulfil our shared ambition.



Alex Filicevas
President,
All.Can International



Eduardo Pisani
Chief Executive Officer,
All.Can International


Advancing Thought Leadership

Efficiency in Cancer Care Blueprint

All.Can launched its updated flagship publication “Building Efficiency in Cancer Care,” in February 2022. It highlights key areas of inefficiency in cancer care and offers a common framework to improve efficiency in cancer care. The blueprint aims to support collaborative policy action that is people-centred and equitable, delivering the best possible health outcomes using the available resources.

Efficient cancer care is more important than ever, given the impact of COVID-19 on diagnoses, treatments and research, and the large backlog of cancer cases faced by health systems. The pandemic has also emphasised the need to build resilience in health systems through efficiency gains.

Urgent and sustained policy leadership and collaborative actions at all levels are crucial to building efficiency in cancer care, aligning policies, practices, technologies, data systems, organisational frameworks, and incentives. All.Can’s blueprint presents broadly applicable recommendations for decision-makers and showcases examples of good practice from the All.Can Efficiency Hub and elsewhere to encourage their wider adoption.



Efficiency is best realised by ensuring all people with cancer have access to a holistic, people-centred and equitable cancer care continuum. The All.Can “Building Efficiency in Cancer Care” blueprint offers a broadly applicable framework to support these objectives. It’s important to strengthen cancer prevention via policies that address modifiable risk factors, evidence-based public health measures (e.g. vaccination), and improving cancer health literacy. Furthermore, we need to ensure early and accurate diagnosis by strengthening evidence-based screening programmes, investing in diagnostic capacities, and adopting precision oncology, among other initiatives.”

Dr. Matti Aapro

European Cancer Organisation and Member of the Board

Cancer Efficiency Metrics study

In June 2022, All.Can released its “Efficiency Metrics in Cancer Care” study, which proposes a set of real-world measures for assessing efficiency in cancer care. The study, produced in partnership with the Health Value Alliance and the University of Southampton, aims to harmonise and set standards in cancer care efficiency globally. The report identifies eight core metrics categories, based on findings from academic articles, cancer registry websites and stakeholder interviews:

- Time to diagnosis
- Percentage of cancers diagnosed through emergency presentation
- Primary care interval
- Time from tissue diagnosis to treatment
- Percentage of patients documented as having seen a Clinical Nurse Specialist (CNS)
- Percentage of patients who received chemotherapy in the last 14 days of life
- Patient experience
- Patient involvement in decision-making

The report was received with great attention at All.Can’s Global Summit, and an implementation phase is envisaged for 2023 and beyond.



All.Can continues to serve a vital role in establishing and publicising insights and solutions to help organisations tackle some of the core challenges in cancer care, while remaining focused on what matters most to the patient. As an example, All.Can’s “Efficiency Metrics in Cancer Care” report has provided an evidence-based blueprint for organisations to use to assess and improve cancer care efficiency, and is now being put into real-world use in the UK, Europe and North America.”

Matt Hickey

The Health Value Alliance – Co-Chair of the Research & Evidence Working Group

“How to improve efficiency in cancer care: Dimensions, methods, and areas of evaluation” in Journal of Cancer Policy

The peer-reviewed article titled “How to improve efficiency in cancer care: Dimensions, methods, and areas of evaluation” was published in the Journal of Cancer Policy. The article, co-authored by several members of All.Can and driven by Bocconi University in Italy, highlights the importance of efficiency in healthcare, particularly in the context of cancer care, where resources are limited and the cost of inefficient allocation can have widespread adverse consequences.

The paper aims to provide a comprehensive overview of the various areas and dimensions in which efficiency can be improved, as well as to establish indicators, methods, perspectives and areas of evaluation to measure gains in cancer care efficiency. The authors present seven policy recommendations for improving efficiency throughout the care pathway and enhancing the measurement of efficiency gains.



Driving Policies and Dialogue

All.Can Global Summit 2022



All.Can held a virtual Global Summit on June 15 and 16 2022, titled 'Taking actions: Implementing Efficiency in Cancer Care Globally', where important issues were discussed, and concrete recommendations were provided to address inefficiencies in cancer care. The summit revolved around the four main themes identified in All.Can's Policy Blueprint:

- Empowering & partnering with people
- Investing in efficient technology
- Implementing a data-driven learning system
- Supporting healthcare professionals

All.Can's mission is to facilitate the exchange of knowledge and best practices, foster cross-country collaboration, and build new partnerships worldwide. To this end, the 2022 Summit was created as a two-day virtual platform for discussions and sharing of best practices among 26 panellists from various countries, including Colombia, Argentina, Mexico, Poland, Australia, Belgium and Nigeria.

The event was attended by over 260 participants from 40 countries, representing all stakeholder groups, such as patient organisations, healthcare professionals and clinicians, data experts, industry, and health system decision-makers. The summit also marked the launch of the "Efficiency Metrics in Cancer Care" report, produced by the Health Value Alliance in partnership with the University of Southampton, on behalf of All.Can International.

The summit showcased national best practices from around the world across the four interrelated dimensions, leading to concrete, replicable and actionable recommendations that can help improve efficiency in cancer care.

Summit Speakers:

- **Dr Cary Adams** - CEO, Union for International Cancer Control (UICC)
- **Dr Ana Paula León** - Deputy Director, La Universidad del Paciente y la Familia (UPF); All.Can Argentina
- **Nadine Boesten** - Policy & Social Inequalities In Health Care (OPIH), Vrije Universiteit Brussel (VUB); All.Can Belgium
- **Gavin Lewis** - Vice President, Global Value And Access, Amgen
- **Dr Virginia Abello Polo, President** - Colombian Association of Hematology and Oncology (ACHO); All.Can Colombia
- **Prof. Rafal Matkowski** - Head of Department of Oncology Surgical Oncology and Breast Unit, Wroclaw Medical University and Lower Silesian Oncology Center; All.Can Poland
- **Dr. Alejandro Mohar** - Biomedical Cancer Research Unit (Biomedical Research Institute, UNAM; Research Directorate, National Cancer Institute, Mexico; All.Can Mexico
- **Cindy Perettie** - Head of Roche Molecular Labs, Roche
- **Prof Walter Ricciardi** - President of the Mission Board for Cancer of European Commission; President of the World Federation of Public Health Associations (WFPHA)
- **Matthew Hickey** - CEO, The Health Value Alliance – Co-Chair of the Research & Evidence Working Group
- **Dr Kay Lakin** - Evaluation and Impact Manager, University of Southampton, UK
- **Dr Ksenia Crane** - Research Fellow, University of Southampton, UK
- **Dr Guillaume Dedet** - Health Policy Analyst, Organisation for Economic Co-operation and Development (OECD)
- **Nigel Hughes** - Scientific Director, Observational Health Data Analytics/Epidemiology at Janssen Research and Development; Project Lead, European Health Data and Evidence Network (EHDEN)
- **Bill Petch** - Co-Chair of the Steering Committee, All.Can Australia
- **Dr Hadi Mohamad Abu Rasheed** - Head of the Professional Development and Scientific Research Department, Qatar Cancer Society
- **Giovanni Gorgoni** - President of the European Regional and Local Health Authorities (EUREGHA); Treasurer of Executive Board of EuroHealthNet
- **Lydia Makaroff** - CEO, Fight Bladder Cancer; President, World Bladder Cancer Patient Coalition
- **Dr Omolola Salako** - Founder of Oncopadi - Co-Founder at Pearl Oncology Clinic Lekki, Nigeria
- **Virpi Sulosaari** - President-Elect, European Oncology Nursing Society (EONS)



Collaboration and collective action are the keys to unlocking efficient cancer care for better patient outcomes. By uniting the cancer community to identify solutions to reduce inefficiencies and improve patient outcomes, the All.Can Global Summit showed us that focusing resources where they matter most for patients is pivotal to making progress on health equity in cancer care. By promoting earlier diagnosis, investing in innovation, and acknowledging our shared responsibility for quality care, we can enable a brighter future for cancer patients worldwide, ultimately aiming to leave no patient behind."

Amadou Diarra

Bristol Myers Squibb - Member of the Board

All.Can's feedback on EU Cancer screening recommendation update

All.Can responded to the European Commission's call for evidence on the EU Cancer Screening Recommendation, expressing support for the new EU Cancer Screening Scheme and the extension of screening to other types of cancers. The feedback emphasised the need to strengthen evidence-based screening programmes, invest in diagnostic technologies and capacities, and improve cancer health literacy among the public through national campaigns involving healthcare professionals. All.Can also highlighted the importance of addressing socioeconomic factors that contribute to late diagnosis, and making screening more accessible to ensure equal access to prevention opportunities. Finally, coordinated action among Member States is needed to prioritise access and allocate adequate funds to cancer screening in national cancer plans.



Screening and early diagnosis is one of the key areas that can boost efficiency of our cancer care systems, as highlighted within All.Can policy blueprint "Building Efficiency in Cancer Care". The publication of the Council of the European Union's updated cancer screening recommendation, in December 2022, has the potential to save thousands of lives across Europe and it is a vital part of the European Commission's Beating Cancer Plan. Together with All.Can, we want to support Member States in implementation of these guidelines to ensure EU patients have access to evidence-based screening programmes and new diagnostic tools, and we hope to further contribute to that field in the months to come."

Agnieszka Krukowska-Van Handenhove
Johnson & Johnson – Co-Chair of the
Public Affairs Working Group

Efficiency in Cancer Care Blueprint launch event

On 23 February 2022, MEP Tomislav Sokol hosted All.Can's virtual launch event for our policy blueprint "Building Efficiency in Cancer Care". The high-level roundtable included speakers from the European Commission, the Union for International Cancer Control (UICC), and All.Can International membership.

The blueprint offers recommendations for decision-makers and showcases good practices to improve cancer care efficiency. The event highlighted the significance of sustained political will and multi-stakeholder collaboration to share, adapt, and scale good practices across international, national and local levels.

The launch event also emphasised the importance of tackling inefficiencies in the entire cancer care continuum to ensure the successful implementation of landmark EU policy initiatives such as the Europe's Beating Cancer Plan and the Horizon Europe Mission on Cancer.

REGISTER NOW

Building efficiency in cancer care: A policy blueprint by All.Can

Virtual launch event hosted by MEP Tomislav Sokol

23 FEBRUARY 2022 | 14:00 - 15:20 CET

#BuildingEfficiencyInCancerCare

[@All.CanGroup](#) [@All.CanGroup](#) [All-Can](#) [All Can International](#)



Improving Systems and Pathways Globally and Locally

Collaborations & Partnerships



Throughout 2022, All.Can engaged in new partnerships and continued collaborating with organisations and initiatives worldwide to improve cancer care efficiency.

Notably, All.Can established a key partnership with the Access to Oncology Medicines (ATOM) Coalition, a UICC-led coalition consisting of over 100 organisations from the global cancer community. The coalition aims to improve patient access to safe, effective and affordable cancer medicines, especially in low- and middle-income countries, through policy changes and innovative financing mechanisms. The coalition also promotes the development and use of generic and biosimilar cancer medicines.

All.Can also continued to collaborate with the European Alliance for Value in Health (EAVH) to promote value-based healthcare (VBHC) in Europe. All.Can contributed to the EAVH's recommendations for advancing VBHC, including prioritising patient-centred care, measuring and improving outcomes, using data to inform decision-making, and supporting innovation.

Additionally, All.Can reinforced its partnership with the EU Health Coalition, supporting the development of eight policy recommendations aimed at strengthening health systems, increasing access to care and improving health outcomes for all Europeans.

All.Can was also invited to join the Sounding Board for the "Innovation - The key to sustainable cancer care" project, led by EFPIA Oncology Platform. Through this project, the initiative aims to showcase real-world examples of how innovative cancer care, including precision oncology and digital healthcare, can improve quality of care, alleviate pressure and help achieve the goals of Europe's Beating Cancer Plan.



The recent OECD report highlights how important it is to have internationally coordinated approaches to health to tackle both emerging threats, as seen with the COVID-19 pandemic, but also chronic disease such as cancer. All.Can International is putting this into practice by developing important international partnerships to promote better cancer care and outcomes, as well as providing a platform for allowing countries to learn from each other about delivering excellent, efficient cancer care.”

Professor Christobel Saunders

University of Melbourne – Vice-President of the Board, Co-Chair of the Research & Evidence Working Group

Furthermore, in response to the conflict in Ukraine, All.Can joined the ECO-ASCO Special Network, a collaboration between the European Cancer Organisation and the American Society of Clinical Oncology, to address the impact on cancer patients and their care. The network’s efforts to improve data collection, develop strategies to enhance access to cancer care, raise awareness of the challenges faced by cancer patients and healthcare providers, and promote collaboration among stakeholders.

In 2022, All.Can was invited to join the EU Cancer Stakeholder Group, a multi-stakeholder platform established by the European Commission to support the implementation of the Europe’s Beating Cancer Plan, a flagship initiative to improve cancer prevention, diagnosis, treatment and care in the EU.

Finally, All.Can submitted applications, as part of various consortia, to three EU-funded projects, of which two have been granted and are scheduled to commence in 2023. All.Can’s commitment to collaboration and advancing cancer care efficiency remains strong.

External Engagements

On 4 February 2022, in honour of World Cancer Day, All.Can released a statement calling on decision-makers to prioritise building efficiency in cancer care as a fundamental aspect of providing equitable access to high-quality care for all those affected by cancer. All.Can further demonstrated its commitment to improving health outcomes by endorsing the recommendations of the EU Health Coalition, which aims to strengthen health systems and increase access to care for all Europeans.

Furthermore, All.Can remains dedicated to promoting advancements in healthcare technology, as evidenced by its endorsement of the White Paper on Medication in Hospital Settings. All.Can joined the Alliance for the Digitalisation of Medication Management in European Hospitals in calling for action to support the digitalisation of hospitals' medication management pathways.

In December, All.Can contributed to the European Alliance for Value in Health's recommendations for advancing Value-Based Healthcare (VBHC) in Europe. These include prioritising patient-centred care, measuring and improving outcomes, utilising data to inform decision-making, and supporting innovation.



2022 was about engaging with policymakers and relevant stakeholders to consider and act upon improving efficiency in cancer care decision-making, as a mean of tackling inequalities throughout the cancer care pathway and building value-based healthcare systems. I was pleased to see that All.Can made its presence felt on the international landscape by providing quality data, insight and best-practice sharing and by continuing to promote patient-centricity and innovation along the whole continuum of care."



Adela Maghear

European Cancer Patient Coalition -
Co-Chair of the Public Affairs Working Group



All.Can at Events – Speaking Engagements 2022:

22 March

Digital Europe Roundtable: “A digital health decade: driving innovation in Europe” – Eduardo Pisani

26–28 April

AMIIF Mexico Innovation Week: “Efficiencies and Innovation in Cancer Care” Panel – Alex Filicevas

5–6 May

EUREGHA CME Webinar: “Good practices for improving the efficiency of cancer treatment in Europe” – Eduardo Pisani

23–24 June

PROMIS Summer School on Health – Eduardo Pisani

7–8 July

ESO/ECO/SPCC: “Improving cancer outcomes and leadership” Course – Matt Hickey

18–20 October

UICC World Cancer Summit (virtual) Session – Alex Filicevas, Ann Marie Baird, Matti Aapro, Matt Hickey, Maria Eugenia de la Fuente

25 October

European Health Forum Gastein – “Cancer Care Efficiency – A path from evidence to implementation” All.Can Webinar

27 October

Fortune Italia Health Forum – Eduardo Pisani

7 November

Emerging Challenges of the future – oncology panel – Thanos Kosmidis, Care Across (on behalf of All.Can International)

8–9 November

Economist Cancer Series – Alex Filicevas, Eduardo Pisani, Matt Hickey

16–17 November

ECO European Cancer Summit: Poster presentation
– Eduardo Pisani & Madalina Iamandei

7 December

European Cancer Forum: Poster presentation – Madalina Iamandei

13 December

After the Council Cancer Screening Recommendations: How can we close the early cancer care gap in Europe? webinar – Alex Filicevas





All.Can in the Media

In January 2022/2023, the International **Brain Tumour Alliance's** annual magazine featured the launch of All.Can's Cancer Care Efficiency Blueprint. The blueprint aims to provide a comprehensive and practical framework for improving cancer care efficiency globally.

In January, **Cancer World magazine** published an article titled "Efficiency in Europe's Beating Cancer Plan," which provided a summary of a webinar from the "Spotlights on Improving Efficiency in Cancer Care" series. The series was organised by the Shared Progress in Cancer Care (SPCC) in partnership with All.Can and SDA Bocconi School of Management, as part of the "Improving Efficiency in Cancer Care: 2020–2021" project.

The Efficiency Metrics study, which aimed to develop metrics for measuring cancer care efficiency in different countries, was the subject of a second article in **Cancer World magazine** in July 2022. The study's findings were also featured in an article in **Health Europa magazine** in June.

In May, Eduardo Pisani, CEO of All.Can International, contributed to **UICC News** with a testimonial on the importance of the Access to Oncology Medicines (ATOM) Coalition and All.Can's support for the initiative.



1352
followers



1036
followers

Efficiency Hub – Lessons Learnt

In 2022, to mark three years of the Hub, All.Can International examined the lessons that can be learnt from the growing collection of examples, now amounting to 44, featured on the Efficiency Hub. Initiatives are selected from across the entire patient care pathway, from diagnosis to palliative care and survivorship; they can be from any country. This think piece, written by The Health Policy Partnership with the input from All.Can members, highlights the kind of solutions that have been identified to address some of the most prominent challenges facing cancer care. The exercise led to the identification of the following lessons about how inefficiencies in cancer care can be effectively addressed in practice:

What key lessons emerge from the Efficiency Hub's examples?



Lesson 1:
Reduce diagnostic delays



Lesson 2:
Move care closer to home



Lesson 3:
Support people beyond active treatment



Lesson 4:
Tailor care to the specific needs of different populations – a focus on children



Lesson 5:
Help people navigate care pathways



Lesson 6:
Develop solutions to maximise local resources



Lesson 7:
Use data and online platforms to enable greater access to precision medicines



Achieving efficiency in cancer care is a key objective in view of the rising costs as well as its complexity. In view of that, identifying trends and lessons about how inefficiencies in cancer care can be effectively addressed in practice have been the focus of All.Can Efficiency Hub's Lessons Learned report. This body of evidence highlights solutions to some of the most prominent challenges facing cancer care today. It is a tribute to the teams who have developed and implemented them, and an inspiration to others to follow suit."



Professor Tit Albreht

Institute of Public Health, Slovenia and Member of the Board

Members

All.Can International's membership reflects its multi-stakeholder representation and includes experts from patient organisations, policymakers, healthcare professionals, researchers and industry. Its 30 organisational and nine individual members contribute their unique knowledge and expertise to improve efficiency in cancer care, act as ambassadors for All.Can, help to publicise its work, events, publications and research findings.



"All.Can is able to drive forward its initiatives thanks to its engaged and multi-stakeholder membership. In 2022, we have made great strides and achieved our objectives for the year. Well done and thank you to all the members for their engagement and commitment!"



Professor Bettina Borisch
Institute of Global Health, University of Geneva, and Member of the Board



National Initiatives


At the end of 2022, All.Can counted 19 countries that have launched multi-stakeholder National Initiatives to bring the All.Can mission into a local context and to further All.Can's objectives.

The most recent addition has been Mexico, who was welcomed into the All.Can community in early 2022.

Throughout 2022, All.Can National Initiatives have continued their efforts to bring stakeholders together, to identify the needs and challenges within their healthcare systems, to formulate policy recommendations and to advocate for the implementation of solutions into national cancer plans and policies.

National Initiatives have met, communicated, discussed and exchanged experiences, achievements and best practices at regular meetings of the All.Can National Initiative Working Group, and via the All.Can International website, newsletter and social media. Moreover, the two internal All.Can Global Summit sessions dedicated to All.Can National Initiatives provided an opportunity for dialogue and exchange of knowledge.

● All.Can initiatives established





Argentina

Achievements 2022

In 2022, All.Can Argentina presented its new policy document "Cancer care in Argentina. Proposals to improve efficiency" that proposes targeted actions to increase efficiency and equity in the continuum of comprehensive cancer care. The document describes four lines of work: promoting sustained prevention policies leading to deep long-term changes; increasing early and correct diagnosis; providing prompt and well-coordinated multidisciplinary treatment; and ensuring palliative care and complementary care.

In addition, All.Can Argentina completed its second survey around the cancer patient's general wellbeing inspired by the PaRIS questionnaire used by the OECD. Carried out together with IPSOS Healthcare, the survey included 328 patients with cancer (with different types and stages) who had been cared for in the primary/outpatient health system during the previous 6 months. According to this survey, almost half of the surveyed cancer patients believe that there is no articulated work between the doctors who attend them and that medical care is not organised "in a way that is functional to the patient's routine." The survey also showed that 60% of cancer patients suffer from anxiety, depression and irritation. Furthermore, in December 2022, All.Can Argentina activities were declared of "health interest" by the Buenos Aires City Parliament.

Cuidado del cáncer: cómo mejorar la eficiencia y centrar la atención en las personas

En una nueva entrega del ciclo de webinars de All.Can Argentina, especialistas en salud analizaron la necesidad de mejorar y transformar la organización del sistema de salud para ampliar su eficiencia y equidad en el continuum de la atención del cáncer.

El cáncer es una patología que continúa creciendo en el mundo, especialmente en el hemisferio sur. En Argentina, la incidencia de nuevos diagnósticos de cáncer continúa aumentando, lo que representa un desafío para el sistema de salud. Este desafío se agrava por la falta de recursos humanos, tecnológicos y financieros, lo que impacta directamente en la calidad de la atención que reciben los pacientes.

En este webinar, expertos en el tema analizaron la necesidad de mejorar la eficiencia y centrar la atención en las personas. Para ello, se presentaron cuatro líneas de trabajo clave:

- Promoción de políticas sostenidas de prevención:** Se destacó la importancia de implementar estrategias de prevención que permitan detectar el cáncer en etapas tempranas, lo que mejora significativamente las opciones de tratamiento y los resultados de supervivencia.
- Incremento de diagnósticos tempranos y correctos:** Se enfatizó la necesidad de fortalecer los servicios de diagnóstico por imagen y patología, así como de mejorar la coordinación entre los diferentes niveles del sistema de salud.
- Provisión de tratamientos oportunos y bien coordinados:** Se abordó la importancia de garantizar que los pacientes reciban el tratamiento adecuado en el momento correcto, evitando interrupciones y duplicación de esfuerzos.
- Garantía de cuidados paliativos y complementarios:** Se resaltó la necesidad de integrar estos cuidados desde el diagnóstico, mejorando así la calidad de vida de los pacientes y el bienestar de sus familias.

El webinar concluyó con un llamado a la acción para que los actores del sistema de salud trabajen de manera coordinada para superar los desafíos actuales y garantizar una atención de calidad para todos los pacientes con cáncer.



Cancer care in Argentina
Proposals to improve efficiency

CASI LA MITAD DE LOS PACIENTES CON CÁNCER CREE QUE NO EXISTE UN TRABAJO ARTICULADO ENTRE LOS MÉDICOS QUE LOS ATIENDEN

Segunda Encuesta Argentina de Pacientes con Cáncer 2022 (IPSOS/IPSOS HEALTHCARE)

ATENCIÓN MÉDICA
El 45% indica que no está organizada de una manera que sea funcional a la rutina del paciente.

ALIANZA DEL AN DE CIUDADANOS
El 58% la considera "útil".

LA MÁQUINA DE ROBAR EL TIEMPO
La burocracia del sistema de salud roba tiempo y angustia al paciente.

ATENCIÓN O ASISTENCIA EMOCIONAL
El 55% de los pacientes indica que recibe.

5 PACIENTES DECLARAN SUS NIVELES DE SATISFACCIÓN
70% en torno a los médicos.
75% en torno a los enfermeros.
42% de los pacientes.
58% de los usuarios.

RECIBE INFORMACIÓN SOBRE SU ENFERMEDAD Y/O TRATAMIENTO
Sistema privado: 42% de los pacientes.
Sistema público: 58% de los usuarios.

LE RESULTA "FÁCIL O MUY FÁCIL" LA GESTIÓN DE TRÁMITES EN LÍNEA (el más frecuente, los turnos)
El 41% en el sistema público.
El 64% en centros privados.

CONSULTA
\$1 minutos
Es el tiempo promedio de la consulta cara a cara.
La calidad de mayor a excelente.
El 81% muestra confianza sobre su médico.

Australia



Achievements 2022

Throughout 2022, All.Can Australia focused its efforts on progressing and expanding its cancer care navigation project in partnership with Healthcare Management Advisors (HMA).

Following the launch of All.Can's Australia Cancer Care Navigator Analysis Report in November 2021, All.Can Australia delivered a proposal for a five-year pilot of the cancer care navigation model to be implemented in Tasmania in conjunction with Primary Health Tasmania. It is estimated that at its peak level of operations, the Tasmanian cancer care navigation pilot has the potential to support approximately 4,913 patients annually and have 14.2 FTE of cancer care navigators to deliver services to those patients, supported by a state-of-the-art app/IT structure. The pilot approach will test and refine the model of care and programme implementation design features, confirm the projected levels of patient benefit, assess the real level of net savings generated by the model in practice, and consider the feasibility and acceptability of the national rollout of the programme. The cancer care navigation pilot will effectively pave the way for a national rollout of the service, helping to reach the goals of the Australian Cancer Plan.


All.Can Australia and HMA's research concluded that pan-cancer care navigation may be able to deliver multiple patient, health system and economic benefits. The budgeted annual cost for a 5-year pilot is \$5.7 million, or \$1,875 per eligible Tasmanian patient per year. The total cost of the five-year pilot is budgeted at \$23.7 m.



The model estimates the proposed Tasmanian cancer care navigation pilot would generate the following net annual economic savings (based on an assumed 20% service utilisation rate): Net savings: \$2.2 million per annum, or \$724 per patient, to the economy through efficiency gains to the health system (based on the budgeted annual service cost of \$5.7 million).

Outlook 2023

All.Can Australia leveraged 2023 World Cancer Day to continue conversations about the importance of cancer care navigation in Australia. The organisation hosted a webinar and brought together Australia's most prominent thought leaders to tackle the issues around cancer care navigation in Australia. In 2023, All.Can Australia is focused on driving better awareness and interest in the proposed Tasmanian cancer care navigation pilot. Continued discussions with State and Federal governments will provide clarity on the pilot scale and design. It is also a priority for All.Can Australia to continue conversations with various patient and consumer organisations who currently have similar navigation programmes that are either active, or in planning.



Austria



Achievements 2022

In 2022, All.Can Austria made significant progress towards further establishing itself as a major player among Austria's stakeholders on cancer-related topics. To raise its profile and define concrete steps, a survey among cancer patients was conducted. The results were reviewed in an open space workshop with 30 high profile attendees from various fields like patient organisations, healthcare professionals, payers, caregivers and media. This resulted in three main project lines along which All.Can will give stimulus for projects and engage in their implementation as far as possible: expansion of technological solutions (smart healthcare) that are already available and the possibilities of digitalisation in the oncology sector, more psychological support, which is also widely communicated, so that the offer is taken up by more people affected, and concrete steps to strengthen the area of oncological nursing staff (e.g. recruitment, training, placement).



As a next step, All.Can is getting involved in a first project with the AKH Vienna hospital to set up and evaluate a new method of cancer patient support via telemedicine.

All.Can Austria also took a major step to gain more visibility with the media and their audiences via a press conference in Vienna which gathered attendees from more than 20 media outlets and resulted in several pieces of positive coverage. Steps were also taken to broaden the membership base of All.Can in Austria.

Outlook 2023

With the addition of new members, All.Can will gain momentum and additional in-depth expertise. The aforementioned telemedicine support project will provide substantial new findings and add to the achievements of the initiative in Austria. An additional project in the field of psychological support will be defined and set up, probably before the end of 2023.



Outlook 2023


All.Can Belgium will continue its Juventas project, with an awareness campaign on the importance of early detection in sarcomas in AYAs launching in February.

A survey on the knowledge of warning signals of breast cancer, testicular cancer and sarcomas, as well as the potential hurdles to seeking help, will be held. The results will give insight into the possible need for further action.

A webinar on the topic, aimed at healthcare professionals, is planned.

All.Can Belgium is looking forward to integrating the Lung Cancer Working Group. The first-year action plan is ambitious and includes the communication of the survey on patient needs.

The OPTIMOC project will receive further support and funding for its final year with a promise of interesting results, and actionable insights will be shared with the government.





Canada

Achievements 2022

Following a comprehensive research project on the current state of cancer diagnosis in Canada, All.Can Canada released the report, "Optimizing Diagnosis in Canadian Cancer Care" in February 2022, which shared key findings and gave recommendations to improve cancer diagnosis for people in Canada.

All.Can Canada began 2022 with a revised, more robust collaborative governance structure informed by Collective Impact and the Constellation network model and a new strategic plan with strategic priorities aligned with our research recommendations to act as our common agenda. Under this revised structure, we began undertaking stakeholder engagement and preliminary knowledge mobilisation of our research findings and


recommendations amongst key stakeholders, both with national professional groups and with provincial policymakers. For context, Canada has 13 provincial/territorial health systems plus five federal ones.

All.Can Canada presented our research findings at several national conferences hosted by the Canadian Centre for Applied Research in Cancer Control, the Canadian Association of Psychosocial Oncology, and the Canadian Association of Nursing in Oncology.

Outlook 2023

In 2023, All.Can Canada will continue to engage with stakeholders to establish and grow collaborative relationships; mobilise our research findings, recommendations and best practices amongst stakeholders; and support the development and use of tools and practices that support people undergoing a cancer diagnosis as well as providers involved in the processes. Ultimately, we aim to influence system-level policies and funding decisions, and to influence professional practices, accessibility, and behaviours, starting with supporting primary care.

All.Can Canada will convene a third, multi-stakeholder roundtable meeting to engage with experts in health equity, the health of Black and Indigenous communities, and with diverse patient populations, to learn what is already happening in cancer diagnosis that meet the needs of people and communities who face systemic barriers, and where they see opportunities to fill gaps.





Colombia

Achievements 2022

During the year 2022, the All.Can Colombia coalition carried out various activities with the aim of improving cancer care in the country and reducing the barriers faced by patients with this disease. The main activities carried out are detailed below:

- The coalition participated in the national public consultation of the administrative act project that will contain the Ten-Year Public Health Plan, providing comments and recommendations on it.
- Dr. Abello represented Colombia at the Global Summit, providing concrete data on out-of-pocket expenses, legal actions, screening, and the impact of COVID-19 on patients, as well as discussing the findings and recommendations of the Great Survey conducted by All.Can Colombia.
- The coalition disseminated the results of the Great Survey: "Barriers Faced by Cancer Patients in Colombia" to patient associations, medical associations, government, and society in general, with the aim of raising awareness about the barriers faced by cancer patients in the country.
- A proposal was initiated to contribute to decision-makers responsible for macro public policy instruments related to cancer, with the aim of improving care and reducing the barriers faced by patients with this disease.
- The coalition conducted a workshop for journalists in which the results of the Great Survey: "Barriers Faced by Cancer Patients in Colombia" were presented in a pedagogical manner, and questions and concerns from journalists on this topic were addressed.
- All.Can Colombia contributed to opening spaces to generate conversations on how to improve cancer care efficiency in the formulation of public policies. On this occasion, the international expert, Dr. Matt Hickey, participated.
- A document was initiated containing legal recommendations on the barriers identified in the Great Survey: "Barriers Faced by Cancer Patients in Colombia", with the aim of generating a discussion with the actors of the health system and seeking solutions to improve cancer patients' care in the country.
- The coalition held an end-of-year meeting in which there was a space for gratitude and recognition for the important work carried out by the members during the year 2022.





Denmark


Achievements 2022

In March 2022, All.Can Denmark hosted another big national conference: "Cancer Summit: Can local communities strengthen early detection?" Attended by some of Denmark's leading experts and politicians, the event's purpose was to present the work of All.Can Denmark and create further awareness of the networks' efforts.

Other activities undertaken by the National initiative include dialogue with the Danish parliament, relevant experts and opinion-makers, establishing a steering group, organising two network meetings, and increased social media activity.

Outlook 2023

All.Can Denmark will continue focusing on early diagnosis and inequality in cancer treatment. In the attempt to have an even greater focus on shaping the Danish policy environment in 2023, All.Can Denmark will launch a position paper with five implementable recommendations for strengthening early access to treatment and inequality in Denmark. The position paper and additional activities aim to improve and re-activate the political cancer debate in Denmark, focusing on early diagnosis.





Germany

Achievements 2022

In 2022, All.Can Germany continued to focus on increasing the quality and availability of cancer care services in rural areas.

Following delays in 2021 caused by the COVID-19 pandemic, All.Can Germany resumed their innovative cancer care activities to enhance and expand outpatient medical services for cancer patients: to support pharmacies to provide advice that meets the cancer patient's needs and to find more ways to recruit and train nursing services.

After the roadshow for analysing the situation in the cancer care system in Germany – which we reported about in the past – the pandemic meant we could only undertake limited activities, especially in the late phases, conclusions and findings. But in the background, All. Can Germany restarted research activities for potential cooperating partners and projects in the field of cancer care up to the beginning of 2022. The restart in 2022 has been accompanied by additional power for the project management, provided by Projekt Partner.

Fortunately, the integrated care project in Templin (Brandenburg) – partly financed by the German fund for innovation in healthcare – offered a second chance to pursue our endeavours, and we agreed about findings and pilot activities to transfer some cancer care from medical professionals to pharmacies and qualified care providers.

In 2022, there were changes in the general conditions that allowed exclusive medical care only by practising physicians. The new legal framework allows qualified pharmacies and care providers to replace practising physicians in defined cases and situations.

At the end of 2022, All.Can Germany began work with the leading oncological pharmacist Klaus Meier to recruit and support selected pharmacies in the Templin region to provide healthcare advice to meet the cancer patient's needs. In 2023, we will follow-up this trial with a study by the University of Greifswald. We will report on the prospect of sustainable success in autumn 2023.

Even in late 2022, All.Can Germany took a first step in the second substitution project, also in the Templin region, to find out how to train and support healthcare and nursing services in the extension of outpatient healthcare provision.

Cancer aftercare was and still is only marginally addressed in the plans of the German government to combat cancer. With improved treatment options, the number of cancer survivors is growing continuously.

Cancer survivors need and deserve an optimised after-care structure. On the one hand, an improved after-care structure offers a clear added value for cancer patients in the form of an optimised quality of life, tertiary prevention and stress and anxiety reduction. On the other hand, these patient benefits can offer great social added value, for example through more flexible reintegration models into the labour market and a reduced need for long-term care.



Greece

Achievements 2022

Following the implementation of the previous year's actions and initiatives, during 2022 All.Can Greece remained focused on its basic and foremost objectives: the improvement of cancer care and treatment during all stages of the disease; improvement in the efficiency of health systems; and access for all cancer patients to state-of-the-art, patient-centred treatment and care.

The most important actions of the Greek initiative in 2022 included:

15 & 16 June, 2022: Participation in the All.Can Global Summit 2022". The majority of All.Can Greece Steering Committee members attended the All.Can Global Summit "Taking actions: implementing efficiency in cancer care globally".

22 June, 2022: All.Can Greece webinar "Quality of Life of Cancer Patients – A cross-sectional approach". All.Can Greece hosted this webinar, comprising lectures from physicians, psychologists, cancer patients' advocates and university professors, and covering the major problems and obstacles affecting the quality of life of cancer patients in Greece.

More specifically, the lectures dealt with the methodology relating to the implementation of the National scale survey. This survey, carried out by All.Can Greece, investigated the quality of life of cancer patients' in Greece.

Significant aspects included: the health literacy of health professionals towards a holistic approach in both cancer care and quality of life of cancer patients; the role and significance of surgical oncology in the improvement of oncological care and treatment; the contribution and importance of healthy living in the improvement of cancer patients' quality of life; cancer patients' social-labour integration; the current situation of cancer patients in respect of the obstacles and barriers they face.

July 2022: All.Can Greece welcomed its 15th member, the Department of Radiology of the University General Hospital of Heraklion, Crete, which was unanimously approved by the All.Can Greece Steering Committee.

12 & 13 November, 2022: Participation of All.Can Greece in 2022 Athens Marathon. A team representing All.Can Greece participated in the Athens Marathon, the most influential and popular annual running event in the country.



Διαδίκτυακή Ημερίδα της All.Can Greece
Ποιότητα Ζωής των Ασθενών με Καρκίνο: Μια δια-τομεακή προσέγγιση
22 Ιουνίου 2022 | 16.00 - 18.20

ΠΡΟΓΡΑΜΜΑ

16.00 - 16.05 | Έναρξη Ημερίδας

16.05 - 16.20 | Καίτη Αποστολίδου
Κολοκυθόρισμα - Χαιρετισμός
Προεδρείο: Αφροδίτη Νόνιν, Γιώργος Πιστόλας

16.20 - 16.35 | Μαρίνος Τσιτσάς
Επιπτώσεις των νέων διαγνωστικών και θεραπευτικών προσεγγίσεων στην ποιότητα της ζωής των ασθενών με καρκίνο

16.35 - 16.50 | Ιωάννης Υφαντόπουλος
Εκτίμηση ποιότητας ζωής των ασθενών με καρκίνο στην Ελλάδα

16.50 - 17.05 | Δημήτρης Παπανικολάου
Συνεχής μεταπαθολογική και υποστήριξη επαγγελματιών υγείας για αποτελεσματική ογκολογική περίθαλψη και φροντίδα

17.05 - 17.20 | Ιωάννης Καραϊσιανάκης
Η συμβολή της χειρουργικής ογκολογίας στην ποιότητα ζωής των ασθενών - Ποιότητα ζωής των ασθενών με καρκίνο πριν και μετά τη χειρουργική αφαίρεση του όγκου

17.20 - 17.35 | Σταυρούλα Ντασιανάκου
Η υιοθέτηση υγιεινού τρόπου διαβίωσης ως καταλύτης για την ποιότητα ζωής & την επιβίωση των ασθενών με καρκίνο

17.35 - 17.50 | Χρύση Καρανάου
Η ζωή του ασθενούς με καρκίνο μετά τη θεραπεία - Κοινωνική & επαγγελματική επανένταξη

17.50 - 18.20 | Σύζησηση - Ερωτήσεις - Συμπεράσματα

AMGEN, AstraZenca, Eli Lilly, MSD, Novartis, Pfizer, All.Can Greece, ΕΛΛΑΚΚ



December 2022: All.Can Greece White Paper. The White paper, entitled "Policy Recommendations for the Cancer Care Control in Greece" has been compiled from Iqvia Hellas with the collaboration of the All.Can Greece members.

The White paper encompasses basic recommendations for the development of a National Cancer Care Plan, for the improvement of oncological care in Greece. Some of the most important recommendations of the White paper are: the need for a National Cancer Registry, ways and actions that will boost and enhance multidisciplinary research and cooperation between all the relevant stakeholders; and an improvement in the provision of cancer care and treatment for all patients.

The results of the survey will be presented at the 7th Annual Conference of the Hellenic Cancer Federation Άρη είναι λάθος αυτό και ο χρόνος και το κείμενο(2023) and in a special press conference aimed at the media, oncology and other health stakeholders.

December 2022: Printing and dissemination of the All.Can Greece White Paper. Upon its completion, the All.Can Greece White Paper "Policy Recommendations for the Cancer Care Control in Greece" was distributed to cancer patients' associations throughout Greece.

Moreover, the White Paper was distributed to oncological hospitals, health professionals, and oncological stakeholders as well as the Greek Ministry of Health and relevant public health stakeholders.

8 December, 2022: All.Can Greece webinar "Patients on the frontline of cancer research". The webinar's target was to inform, sensitise and motivate cancer patients, health professionals, policymakers and the public on the significance of cancer patients' participation in cancer care research and oncological surveys as well as the importance of equal and unrestricted access to innovative state-of-the-art tech therapies. These aims were discussed in a series of lectures.

Moreover, it aimed to promote the participation of cancer patients in cancer care surveys in general and to present policy recommendations that will enhance the improvement of personalised and patient-centred cancer care and treatment.

Outlook 2023

All.Can Greece has grown to be one of the most reliable interlocutors when it comes to cancer care in Greece. The National Initiative will continue to implement actions with an increased added value for cancer patients, healthcare professionals and the healthcare system, such as scientific webinars and informational events in oncology hospitals, and direct consultations with the country's major health and social policymakers, notably the Ministry of Health.

...Οι ασθενείς στην πρώτη γραμμή έρευνας για τον καρκίνο...

Διαδικτυακή Ημερίδα

8 Δεκεμβρίου 2022, 16:00 έως 17:45

AVGEN AstraZeneca Bristol Myers Squibb MSD Roche

ΓΡΑΦΕΙΟ ΚΑΡΚΙΝΟΥ ΕΛΛΑΔΟΣ ALL.CAN GREECE



Israel

Achievements 2022

The All.Can International initiative and its Mission was introduced by All.Can Israel to relevant officials throughout the Israeli healthcare ecosystem during 2022, including the Israel Ministry of Health, Medical Centres, Research Institutes, and relevant Patient Organisations.

Outlook 2023

Collaborations between All.Can Israel and the Assuta Health Services Research Institute and Tel Aviv Sourasky Medical Center began in 2022.

As a part of the collaboration, we are conducting a 'Patient Survey Research' together. We wish to gain an understanding of crucial 'Patient Journeys' and their major weaknesses. Approval by the Helsinki Committee is expected in March 2023.



Italy

Achievements 2022

In 2022, All.Can Italy aimed to put into practice and give value to all the research and studies that were initiated in the previous two years.

It was a year of great visibility for the platform as we managed to reach out to institutions and policymakers, showcasing All.Can's projects.

First of all, All.Can Italy wrote an article for the FAVO report on national oncology patient day. The article was about the need for fast approval of a national oncology plan that would be in line with the Europe's Beating Cancer Plan. We discussed that article during the conference and solicited institutions to keep up with the latest innovation.

Second, we promoted a wholly Italian best practice in onco-haematology: a programme adopted by hospital Policlinico Umberto I in Rome. The hospital executed a programme to take care of haematology patients choosing the most suitable care setting between home and hospital.

This project resulted in huge savings due to reduced hospitalisations, and led to better wellbeing for patients because they could be treated closer to their families and loved ones. Our goal was to select this best practice, upload it on the All.Can efficiency hub and share it with institutions.

The interaction with policymakers resulted in a press conference at the Senate, after which we hope many more hospitals and health districts will be able to follow this lead.

Outlook 2023

All.Can Italy is already working on new projects for 2023 and keeps building solid relationships with institutions to improve the efficiency of cancer care. In this, we can now count on the support of a new spokesperson, Paolo Bonaretti, whose expertise can further improve All.Can's successes and ambitions.



Osservatorio
sulla condizione
assistenziale dei
malati oncologici

14° Rapporto sulla
condizione assistenziale
dei malati oncologici

Roma, 12-15 maggio 2022
XVII Giornata nazionale del malato oncologico

Realizzato da:





Korea

Achievements 2022

All.Can Korea conducted the “Development of an inter-patient support programme for psychological support for cancer patients” study with an external researcher. The aim was to develop a protocol to establish the provision of accessible psychological support services through the local community to cancer patients who experience psychological or emotional distress.



The goal of the research was to teach cancer survivors how to provide psychological support, and foster “peer volunteers”, thus developing a standardised programme for such support. A test operation of the developed support programme and curriculum for fostering peer volunteers evaluated its feasibility and applicability.

A policy forum, “Unattended checkpoints in cancer management: the solution is in the mind of cancer patients 2”, was organised to present the results of the research that had been conducted throughout the year. The forum was hosted by Korea’s National Assembly ‘Well Dying Research Council for a Dignified Life’, with whom All.Can Korea has maintained a relationship since 2021 when the first policy forum was organised.

During the forum, in addition to presenting the research, the research participants shared their thoughts about the support programme, and a panel of experts in various relevant industries (including government, academic, media and healthcare representatives) discussed how to derive a more practical and viable policy support measure for such services.

In 2022, All.Can Korea focused on taking steps that could lead to real-world changes to meet the psychological needs of cancer patients. A policy proposal for psychological support for cancer patients was also delivered to various political stakeholders so that future health and welfare policy agendas would include psychological support for cancer patients.

Outlook 2023

All.Can Korea is looking to continue securing leadership in psychological support of cancer patients within Korea in 2023, considering various activities such as expanding on the study done in 2022, for example.

Mexico

Achievements 2022

In 2022, All. Can Mexico made significant progress in advancing its mission of improving cancer care and reducing inefficiencies in the healthcare system. The following are some of the key achievements made by the initiative in 2022:

Creation of the Executive Committee All. Can Mexico: The executive committee was established to represent the associated groups to All. Can: researchers, physicians, patient associations, and founding partners. The committee is composed of Dr. Eduardo Lazcano, Head of the Institute of National Public Health; Kenji Lopez, Founder and Head of the association Cancer Warriors of Mexico; and Cristóbal Thompson, Executive President of the Mexican Association of Pharmaceutical Research Industries, A.C.

Increase in Stakeholders: As of November 2022, the initiative had 112 participants, with 35% representing support groups for patients, 65% being health professionals, and 5% founding partners. The increase in stakeholders signifies the growing support for All. Can Mexico's mission and its relevance in the healthcare system.

All.Can 2022 Summit: The winner of the All. Can 2022 Summit was the physician Karla Unger, who presented her innovative project to improve the efficiency of cancer care in Mexico. The project addresses the urgent need to reduce waiting times for breast cancer treatment at Mexico's National Cancer Institute (INCan), which has seen an increase in the number of cases referred for treatment. The expected outcome of the program is the development of an effective model that can serve as a guide for other cancer centers facing similar challenges.


Outlook 2023

Looking forward to 2023, All. Can Mexico has set its sights on achieving the following milestones:

All.Can Summit 2023: The All.Can Summit 2023 will be launched to support and encourage cancer investigation, bringing together experts from around the world to collaborate and push the boundaries of what's possible in the fight against cancer. The summit will provide a platform for stakeholders to exchange ideas, discuss new initiatives, and explore ways of improving cancer care in Mexico.

Increase in Stakeholders: All.Can Mexico aims to increase the number of stakeholders in the initiative, particularly patient associations and investigators. The increase in stakeholders will help the initiative to expand its reach and impact in the healthcare system.

In conclusion, All.Can Mexico has made significant strides in 2022 towards improving cancer care and reducing inefficiencies in the healthcare system. The establishment of the executive committee, the increase in stakeholders, and the All.Can Summit 2022 are testament to the initiative's relevance in the healthcare system. All.Can Mexico's outlook for 2023 is promising, with the launch of the All.Can Summit 2023 and the aim to increase stakeholders. All.Can Mexico remains committed to its mission and looks forward to contributing to the improvement of cancer care in Mexico.





Norway

Achievements 2022

Throughout 2022, All.Can Norway has worked purposefully to position our two focus areas on the agenda in the Norwegian cancer debate:

Prehabilitation – more effective preparation of patients, which in turn gives better treatment results and quicker rehabilitation. Physical activity, diet, smoking cessation and more knowledge,

Reliable & Safe discharge – what cancer patients should expect when discharged from the hospital, a home care programme.



As part of this work, the steering group decided to take this one step further by establishing the patient perspective even more strongly through a new concept/term: "Patient perceived quality."

Throughout the year, All.Can Norway conducted a number of focus groups with representatives from patient organisations, next of kin and healthcare personnel. The results are compiled in a report that will be launched in 2023.

All.Can Norway has also executed a social media campaign to highlight concrete results from projects with prehabilitation and safe discharge. Here we have received testimonials from healthcare personnel, patients and public bodies.

For the third year in a row, we have collaborated with the Norwegian organisation "Cancer Compass" (Kreftkompasset). This has resulted in the launch of an audiobook version of the book "Life after Cancer", in addition to a new roadshow in several of the cities and hospitals in the northernmost part of Norway. We have also collaborated on several podcasts that are distributed on Kreftkompasset's platform.

Outlook 2023

We plan to launch the All.Can Norway Report: "Patient quality perception – focus groups with cancer patients, next of kin and health personnel."

There will follow a general awareness and outreach campaign based on the Report.

All.Can Norway plans to undertake political and stakeholder outreach through meetings, seminars and round tables. We also aim to work closer and establish a relationship with new potential members.

Etter innføring av prehabilitering er antall reoperasjoner halvert

Pasientdøgn på sykehuset er også betydelig redusert

All.Can Norge



Poland

Achievements 2022

Report "Standards of patient service as part of the treatment in breast cancer units". In the first half of 2022, All.Can Poland continued to disseminate recommendations from this report, organising two local workshops for the management and personnel of oncology hospitals. The project was also presented at the All.Can

Global Summit in June by Prof. Rafał Matkowski, Head of Department of Oncology, Surgical Oncology and Breast Unit, Wrocław Medical University and Lower Silesian Oncology, Pulmonology and Hematology Center.

Project "Optimization of use of hospital drugs". All.Can Poland coordinated work on this project, which was initiated by the Polish Oncology Society, the Polish Pharmacoeconomy Society and Country Consultant in the field of hospital pharmacy. Optimal drug management in a hospital pharmacy is a complex issue. Properly implemented, in a well-equipped drug preparation laboratory, by personnel with appropriate qualifications, experience and knowledge, the losses are minimised and technological surpluses are maximised. This, in turn, translates into the profitability and cost-effectiveness of the therapy. It also promotes patient safety by improving the quality of care. The project recommendations are to be presented to decision makers in the first quarter of 2023 in order to support their implementation.

Report "Diagnosis of changes in oncological care in Poland 2022". At the end of 2022, All.Can Poland prepared this report, which analyses the changes that have taken place in the field of oncological care in 2022. The All.Can Polska Steering Committee identified the achievements but also the unmet needs and challenges that require action in order to improve the stability and efficiency of oncological care in Poland. The report has been posted on social media sites and delivered to decision makers from MoH, National Health Fund, Parliamentarians and PAGs.




OPTIMALIZACJA GOSPODARKI LEKIEM W WARUNKACH SZPITALNYCH



Optymalna gospodarka lekiem w aptece szpitalnej to złożone zagadnienie. Prawidłowo realizowana, w ramach dobrze wyposażonej pracowni przygotowania leku, przez personel posiadający stosowne doświadczenie i wiedzę pozwala na minimalizację strat i maksymalizację uzyskiwanych nadmiarów technologicznych. To z kolei przekłada się na opłacalność terapii i ich efektywność kosztową.

**PODCZAS SPORZĄDZANIA LEKÓW DOCHODZI
DO POWSTAWANIA STRAT – DLACZEGO?**



Outlook 2023

The All.Can Poland Steering Committee decided to concentrate on two priorities:


Project "Optimization of use of hospital drugs". Further work is needed to implement recommendations, including meetings with decision-makers at the central level (MoH, NHF) and circulation via social media.

Project "Improvement of access to molecular diagnostics in order to increase the effectiveness of oncological care". This report is to be prepared in collaboration with patient organisations and experts.

Additionally, there is a plan to work within the recommendations of the All.Can Cancer Efficiency Metrics Study in order to support implementation of efficiency and quality of care measures in Polish oncological care.

Report "Diagnosis of changes in oncological care in 2023". In quarter 4 of 2023, the members of the initiative will prepare this report, to summarise the achievements and unmet needs in oncological care in 2023.

All.Can Poland will continue to provide commentary on important issues and promote education on prevention through reports and social media activity such as Facebook and Twitter.






Spain

Achievements 2022

All.Can Spain was consolidated in 2022, thanks to the involvement of some of the most prestigious cancer institutions in Spain, to contribute to improving patient care policies.

During 2022, the Scientific Committee of All.Can Spain published its first report, focusing on identifying recommendations to overcome the fragmentation and lack of coordination that still exist, and aiming to mitigate the patient's feeling of sometimes being "lost in the system", which increases their uncertainty and concern when faced with suspected cancer.

To this end, the report "The cancer patient experience: optimizing the circuit and improving care and coordination until diagnosis. Eight recommendations for real change" has identified eight recommendations to ensure and optimise the quality of care in the first phase of the circuit.



Following its publication in December, the report was presented at the Spanish Parliament on 1 February, in the framework of World Cancer Day. The meeting was attended by the health representatives of the main political parties in Congress, who were particularly grateful for the celebration of this event, reinforcing the bridges between the main initiatives in the fight against cancer and the representatives of popular sovereignty, favouring the exchange of ideas and proposals for improvement.

As a result of this presentation, two parliamentary groups have already presented parliamentary initiatives that include some of the Report's recommendations and identify All.Can Spain as a benchmark in knowledge generation and as a solution provider. The PNL presented by the Ciudadanos Parliamentary Group was approved by a very large majority (307 votes in favour), thus consolidating the leading role of All.Can Spain in the service of public institutions, the health system and, most importantly, the neglected needs of patients.

Sweden



Achievements 2022

During Almedalen 2022 (an annual festival in Sweden described as “a democratic meeting place that everyone can join and co-create”), All.Can Sweden organised a seminar on the subject of equal healthcare in Sweden by measuring and following up. The seminar was a continuation of the work in our policy paper, “Equal cancer care”, which was published in 2021. With the help of material that was

created during the seminar, we have continued to spread and draw attention to the topic of equal care on our social channels during the autumn.

In several reports and investigations, the problem of unequal care has been raised, but why are we not getting further on the issue? As we see it, part of the problem lies in the lack of relevant follow-up and access to data.

On 6 July, the seminar “How do we make Swedish healthcare equal - measure and follow up!” was held. The questions above were discussed with the goal of creating a dialogue about the way forward that aims to create more equal healthcare.

Our guests represented several important parts of Swedish healthcare. We had people who represented the patient perspective, people from SKR and the social committee and people who represented research, among others.

During the seminar, we discussed the challenges in achieving equal care, questioned whether we are measuring the right things, examined the role of patients, the way forward, and patient involvement. Below you can read about part of the discussion that was held. The seminar overall was a success, because we had the opportunity to raise one of the most important questions for Swedish healthcare.





Challenges for equal care:

A new kind of frustration is now being felt by the country's cancer patients. The industry is very united about what needs to be done, but the frustration of patients lies in wondering how and when it should be done. We must move from producing documentation about what we should do, to actually implementing the recommendations. It's about getting this into actual operation within healthcare.

Do we measure the right things?

Data are not always available to enable us to find the right information to reach the right conclusion. This is a frequent frustration when carrying out research.

When working with patient data, it is important to know who should have access to this data, i.e. where it is needed. Here, a distinction is made between primary and secondary data. Primary data are data that relate directly to care and are used in daily patient work. Secondary data are data that must be removed from care and must be researched with or used for some other purpose.

The role of the patients

Patients also bear a certain amount of personal responsibility in the matter of data sharing.

The beauty of it all is that the vast majority of patients are happy to share their data, as long as they feel it is safe. Many patients already share large amounts of data in a variety of apps, so the will is there. Security is extremely important given the sensitivity of the data you share as a patient.

The way forward

The more we measure, the more we look, the more we find the inequalities and can access them. We need access to information, but we also need decision support. Since the 1980s, Sweden has legislated for good and equal healthcare, and we still talk about it. Perhaps instead of doing more of what we already do today, we should do completely different things.

Involvement of patients

It is time we find a structured way to involve patients in our work. In doing so, we also build structures for patients that support new patients. Once we have decided that there will be patients involved at all stages, then of course it can be implemented, but you must find the structured way.

Switzerland



Achievements 2022

In 2022, All.Can Switzerland concentrated on two main issues: they focused on important projects that are co-financed and supported by All.Can Switzerland; and an internal process was initiated to focus the vision and goals of All.Can Switzerland. These efforts will be continued in 2023.

With regard to the projects, there are various highlights to report: The project launched in the summer of 2021, which aims to optimise outpatient cancer care, has continued to gain momentum. There have been 26 patients involved in the project so far, and the following project goals were achieved after one year: Acceleration of processes, which reduces the length of stay of patients in the outpatient department; increasing patient satisfaction by speeding up processes; relief of medical resources; and further development of nursing competences and increase of the attractiveness of the profession (job enrichment).

In July, the article on the Needs Assessment study "Game changer in Cancer Treatment in Switzerland" was published in the Journal of Cancer Policy. All.Can Switzerland commissioned the "Institute of Global Health at the University of Geneva", Prof. Bettina Borisch and Dr. Marta Lomazzi, for this project.

Another milestone was the development of a guide for the implementation of "Value Based Healthcare", which was developed within a cooperation between the Swiss Forum for Integrated Care fmc and All.Can Switzerland, and is now available in three languages.





Outlook 2023

The focus of All.Can Switzerland for the year 2023 is on the implementation of the revised vision for the association, the monitoring and completion of projects as well as the expansion of the activities of the working groups.

At the Board Strategy Meeting on 24 October, 2022, in Zug, the vision and goals of All.Can Switzerland were focused and revised. The All.Can Board decided to engage in the area of "survivorship" with a focus on "aftercare" and "equal opportunities". The following goals have also been established through 2025:

- "Survivorship" services/resources are available in a service region for health professionals, counseling services, and affected individuals.
- All.Can to be associated with the "Equal Opportunity Vision".
- Raise awareness that there is only partial equity in cancer care, but much good already exists and is being done on a small scale.
- Create/improve training/qualifications for professionals who care for "survivorship" patients.
- Broadening the membership base of All.Can. Make funding for All.Can more broadly based, with pharmaceutical companies contributing a maximum of 50% of the All.Can budget in the medium term.

The vision and strategic goals will guide the priorities and activities for All.Can Switzerland members and their institutions in the coming months.





United Kingdom

Achievements 2022

In 2022, All.Can UK continued to advance the recommendations from their report "All.Can UK: Placing the psychological wellbeing of people with cancer on an equal footing to physical health".

In particular, All.Can UK focused on the recommendation to take steps to improve the recognition of the important role that health charities play in supporting patients' mental health needs. This involved finalising an infographic tool which maps the psychosocial support services provided by All.Can UK's Working Group members. The infographic includes information about the support available to cancer patients throughout the cancer care pathway and aims to make it easier for NHS staff to signpost cancer patients to these services.

A key success for All.Can UK in 2022 was working closely with the Living With and Beyond Cancer team at NHS England to secure a commitment to include their infographic in a toolkit. This toolkit was disseminated to healthcare professionals (HCPs) across the UK and as a result is now being used by HCPs to help patients to more easily access support.

All.Can UK have also shared their infographic with key stakeholders at the Royal College of Nursing and Royal College of Psychiatrists, who agreed to disseminate the infographic further among their members, including nurses and psychiatrists working directly with cancer patients.

Finally, at the beginning of 2022, All.Can UK commissioned the Office of Health Economics (OHE) to conduct a literature review and develop a value proposition which estimates the efficiency savings psychosocial support interventions can deliver for the system. The aim of this project is to address the challenges highlighted in All.Can UK's 2021 HSJ roundtable and subsequent article around the 'conceptual separation' that exists between physical and mental health.

All.Can UK were invited to present the initial findings from this analysis at an NHS England conference in December on "Improving Mental Health Support for People Affected by Cancer". The conference was attended by senior NHS officials and patient group representatives, including:

- Cally Palmer, National Cancer Director, NHS England and Improvement
- David Fitzgerald, Programme Director, NHS Cancer Programme, NHS England and Improvement
- Ceinwen Giles, Chair of the Patient & Public Voices Forum, NHS Cancer Programme and All.Can UK Working Group member

Outlook 2023


In 2023, All.Can UK will be publishing a detailed report on the commissioning of psychosocial support services which summarises the OHE's findings and provides further analysis. One of the findings which will be included in the report is that psychosocial interventions for cancer patients could save the NHS as much as £1,083 per patient on average in the first year after the intervention.

All.Can UK plans to take this report to political and healthcare system stakeholders to discuss how reductions in downstream escalations can translate into cost savings and improved efficiency for the system. All.Can UK also intends to use the report as a tool to relaunch All.Can in the UK and assert their position as the leading group advocating for improvements to all elements of the cancer patient pathway.

Finally, as the 2024 General Election approaches in the UK, All.Can UK will be developing a set of 'policy asks' to share with key decision makers at a planned roundtable with the All Party Parliamentary Group (APPG) on Cancer. Following the roundtable, All.Can UK will ask members of the APPG and other relevant parliamentarians to take All.Can UK's asks to their party leaders for inclusion in party manifestos.

Cancer:
Out of 
Sight 
Out of 
Mind

All.Can UK:
Placing the psychological wellbeing of people with cancer on equal footing to physical health



Join us. Work with us. Together, we All.Can.

All.Can International
Rue du Luxembourg 22-24
BE-1000 Brussels
Tel: +32 2 761 66 73
secretariat@all-can.org
www.all-can.org

 All.Can

 @AllCanGroup

All.Can International is a not-for-profit organisation (ASBL) registered in Belgium.
Its work is made possible with financial support from Bristol Myers Squibb, Roche,
MSD, Johnson & Johnson and Illumina. Additional financial support for projects has
been provided by Amgen



Changing cancer care together